The treatment of severe myasthenia gravis with immunosuppressive agents.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000380:Agranulocytosis / Q000139:chemically induced; D000630:Aminopterin / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D013997:Time Factors
D002800:Cholinesterase Inhibitors; D007166:Immunosuppressive Agents; D003609:Dactinomycin; D015122:Mercaptopurine; D000630:Aminopterin; D001379:Azathioprine; D008727:Methotrexate